CPH:ZEAL — Zealand Pharma - Presentation at ADA Scientific Sessions
May 31, 2025, 10:00:00 PM UTC
Summary
Zealand Pharma A/S (Nasdaq: ZEAL) will present results from Part 1 of the Phase 1b trial for its drug dapiglutide at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Illinois, on June 1, 2025. Dapiglutide is a GLP-1/GLP-2 receptor dual agonist that is under investigation for treating conditions related to obesity. The company has recently entered a significant partnership with Roche to co-develop and co-commercialize its amylin analog, petrelintide, enhancing its pipeline's potential and anticipated revenues. Zealand Pharma reported strong progress in its clinical trials and has appointed a new Chief Scientific Officer to lead its research efforts.
Company
Zealand Pharma (CPH:ZEAL)CPH — Health Care,
Similar Events
Zealand Pharma A/S - Capital Markets Day in London
Zealand Pharma A/S will host a Capital Markets Day in London on December 11, 2025, where management and external experts will discuss the company's efforts in developing innovative peptide-based medicines, particularly in obesity treatment. Amidst a transformative partnership with Roche for its lead product petrelintide, Zealand Pharma aims to solidify its position in the weight management market. The collaboration involves shared profits and milestone payments, with total deal consideration reaching USD 5.3 billion. The event will provide insights into the company’s financial outlook and ongoing trials, with a focus on how these initiatives may impact future performance.
Investor EventPresentation at ADA’s 85th Scientific Sessions
Glucotrack, Inc. announced that it will present data on safety and performance from its first-in-human trial of an implantable continuous blood glucose monitoring system at the American Diabetes Association’s 85th Scientific Sessions in Chicago, scheduled for June 20-23, 2025. This presentation aims to highlight advancements in diabetes management technology, which may have significant implications for both the company's future growth and investor interest. The data to be shared could influence market perceptions of the product's effectiveness and safety.
OperationalZealand Pharma A/S - Q1 2025 Conference Call
Zealand Pharma A/S will host a conference call on June 1, 2025, at 2:00 PM CET / 8:00 AM ET to discuss financial results for Q1 2025. The call will feature CEO Adam Steensberg and other executives discussing the company's significant developments, including a transformative partnership with Roche to co-develop petrelintide, an amylin analog targeting obesity. This partnership, valued at approximately $5.3 billion, aims to establish a leading franchise in weight management. Key Q1 results showed a revenue of DKK 8.1 million, with expectations of a $1.4 billion upfront payment from Roche anticipated in Q2 2025. The conference call will also provide insights into the company's clinical pipeline and operational updates.
conference callZealand Pharma A/S - Financial Results for Q2 2025
Zealand Pharma A/S announced its financial results for the second quarter of 2025 on August 14. The biotechnology company, known for developing peptide-based medicines, highlighted its strategic partnership with Roche for the co-development of petrelintide, which aims to manage obesity. Zealand Pharma's recent financial report indicated a significant decrease in revenue, reporting DKK 8.1 million for Q1 2025 compared to DKK 15.1 million in Q1 2024. Despite operating expenses rising to DKK 415 million due to collaboration costs, the company anticipates an upfront payment of USD 1.4 billion from Roche in Q2 2025, part of a broader deal worth USD 5.3 billion, which may materially impact its growth trajectory and operational stability.
Financial Report